TY - JOUR
T1 - Plasma levels of soluble glycoprotein 130 in acute myocardial infarction
AU - Ichiki, Tomoko
AU - Jougasaki, Michihisa
AU - Setoguchi, Manabu
AU - Shimokawahara, Hiroto
AU - Nakashima, Hitoshi
AU - Matsuoka, Tatsuru
AU - Sonoda, Masahiro
AU - Nakamura, Kazuhiko
AU - Minagoe, Shinichi
AU - Tei, Chuwa
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2007
Y1 - 2007
N2 - Objectives: Soluble glycoprotein 130(sgpl30), a circulating form of receptor subunit for the interleukin (IL)-6 cytokine family, modulates the biological actions of its Jigands as an inhibitory regulator. The role of sgp 130 in cardiovascular diseases such as acute coronary syndrome remains unknown. Methods: Plasma levels of sgpl30 were examined by enzyme-linked immunosorbent assay in 33 patients with acute myocardial infarction (AMI; mean age 67 ± 2 years, 21 males and 12 females), who were admitted to our hospital within 24 hr of onset of AMI and survived for 4 weeks. Results: Plasma sgp 130 levels were significantly higher at admission (260.5 ± 7.3 ng/m/), and were significantly lower from day 2 to day 5 (202.4 ± 5.1 ng/m/at day 3) as compared with normal control subjects (n = 38, 227.1 ± 5.6 ng/m/). The lowest sgp130 levels inversely correlated with white blood cell count at admission (r = - 0.42, p < 0.05) and with peak C-reactive protein levels (r = - 0.43, p < 0.05). Additional in vitro study revealed that incubation of AMI plasma with exogenous IL-6 plus soluble IL-6 receptor resulted in a decrease in plasma sgp 130 levels, suggesting the possible reason for reduced plasma sgp 130 levels in AMI. Conclusions: The present study indicates that plasma sgp 130 levels were modulated during the time course of AMI and inversely associated with inflammation in AMI.
AB - Objectives: Soluble glycoprotein 130(sgpl30), a circulating form of receptor subunit for the interleukin (IL)-6 cytokine family, modulates the biological actions of its Jigands as an inhibitory regulator. The role of sgp 130 in cardiovascular diseases such as acute coronary syndrome remains unknown. Methods: Plasma levels of sgpl30 were examined by enzyme-linked immunosorbent assay in 33 patients with acute myocardial infarction (AMI; mean age 67 ± 2 years, 21 males and 12 females), who were admitted to our hospital within 24 hr of onset of AMI and survived for 4 weeks. Results: Plasma sgp 130 levels were significantly higher at admission (260.5 ± 7.3 ng/m/), and were significantly lower from day 2 to day 5 (202.4 ± 5.1 ng/m/at day 3) as compared with normal control subjects (n = 38, 227.1 ± 5.6 ng/m/). The lowest sgp130 levels inversely correlated with white blood cell count at admission (r = - 0.42, p < 0.05) and with peak C-reactive protein levels (r = - 0.43, p < 0.05). Additional in vitro study revealed that incubation of AMI plasma with exogenous IL-6 plus soluble IL-6 receptor resulted in a decrease in plasma sgp 130 levels, suggesting the possible reason for reduced plasma sgp 130 levels in AMI. Conclusions: The present study indicates that plasma sgp 130 levels were modulated during the time course of AMI and inversely associated with inflammation in AMI.
KW - Blood cells
KW - Cytokines
KW - Myocardial infarction
KW - Pathophysiology
UR - http://www.scopus.com/inward/record.url?scp=34848894237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848894237&partnerID=8YFLogxK
M3 - Article
C2 - 17802693
AN - SCOPUS:34848894237
SN - 0914-5087
VL - 50
SP - 101
EP - 109
JO - Journal of Cardiology
JF - Journal of Cardiology
IS - 2
ER -